Homepage > Company > Media > Pharma News > 2021 > Krystal Biotech Touts Positive Results for Gene Therapy Treating Tissue Disease

Krystal Biotech Touts Positive Results for Gene Therapy Treating Tissue Disease

Krystal Biotech has released positive phase 3 results for its gene therapy Vyjuvek (beremagene geperpavec) developed to treat dystrophic epidermolysis bullosa (EB), an inherited connective tissue disease.

The late-stage study showed that Vyjuvek, administered topically, induced 67 percent complete wound healing vs. 22 percent in the placebo cohort at six months.

Krystal said Vyjuvek is the first gene therapy developed to treat dystrophic EB that has successfully completed a double-blinded phase 3 trial. The company plans to use the trial results to support an FDA biologics license application submission during the first half of next year.

November 30, 2021

https://www.fdanews.com/

Read also

AskBio’s AB-1002 gene therapy receives FDA Fast-Track status

The US Food and Drug Administration (FDA) has granted fast-track designation to Bayer subsidiary Asklepios BioPharmaceutical’s (AskBio) investigational gene therapy AB-1002, aimed at...

“Lack of harmonisation in Europe” hindering gene therapy growth

The future of cell and gene therapy access in Europe could be more precarious than across the pond.

Moderna stock on track for the eighth consecutive day of losses

Moderna shares are trading in the red on Friday, on track for the eighth consecutive day of losses. Stock down 1.28% at $100.70. MRNA has lost about 29.6% in the last 12 months and YTD, the st...

Alvotech moves to bring its Humira biosimilar to US market

Hot on the heels of a US Food and Drug Administration (FDA) approval for Alvotech and Teva Pharmaceuticals’ Simlandi (adalimumab-ryvk), Alvotech has announced a long-term agreement w...